Global Information
회사소개 | 문의

대장암 : 파이프라인 리뷰

Colon Cancer - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 06월 상품 코드 229732
페이지 정보 영문 782 Pages
가격
US $ 2,500 ₩ 2,822,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,644,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,466,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


대장암 : 파이프라인 리뷰 Colon Cancer - Pipeline Review, H1 2018
발행일 : 2018년 06월 페이지 정보 : 영문 782 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

대장·결장 직장암은 대장(결장) 또는 직장(대장의 끝부분)에 발병하는 암입니다. 단일 원인은 특정할 수 없습니다. 거의 모든 대장암은 비암성(양성) 폴립에서 시작하여 서서히 암으로 진행합니다. 많은 경우, 증상은 없습니다. 복통 및 하복부의 압통, 혈변, 설사, 변비 또는 배변 습관의 변화, 원인 불명의 체중 감소 등의 증상이 나타납니다. 치료에는 외과 수술, 방사선 요법, 화학요법등이 포함됩니다.

대장암 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업의 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

목차

서론

대장암 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

조사중인 치료제 : 대학/연구기관별

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품
  • 미확인 단계 제품

개발중인 제품 : 기업별

조사중인 제품 : 대학/연구기관별

치료제 개발에 참여하고 있는 기업

치료제 평가

  • 단일요법의 경우
  • 병용요법의 경우
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

휴지 상태 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

KSA 16.10.06

List of Tables

  • Number of Products under Development for Colon Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Colon Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
  • Colon Cancer - Pipeline by 4P-Pharma SAS, H1 2018
  • Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
  • Colon Cancer - Pipeline by Adamed Sp z oo, H1 2018
  • Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018
  • Colon Cancer - Pipeline by Aduro BioTech Inc, H1 2018
  • Colon Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
  • Colon Cancer - Pipeline by Affimed GmbH, H1 2018
  • Colon Cancer - Pipeline by AGV Discovery SAS, H1 2018
  • Colon Cancer - Pipeline by AIMM Therapeutics BV, H1 2018
  • Colon Cancer - Pipeline by AlfaSigma SpA, H1 2018
  • Colon Cancer - Pipeline by Alligator Bioscience AB, H1 2018
  • Colon Cancer - Pipeline by Ambrx Inc, H1 2018
  • Colon Cancer - Pipeline by Amgen Inc, H1 2018
  • Colon Cancer - Pipeline by AndroScience Corp, H1 2018
  • Colon Cancer - Pipeline by ANP Technologies Inc, H1 2018
  • Colon Cancer - Pipeline by Aphios Corp, H1 2018
  • Colon Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
  • Colon Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
  • Colon Cancer - Pipeline by Asana BioSciences LLC, H1 2018
  • Colon Cancer - Pipeline by aTyr Pharma Inc, H1 2018
  • Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Colon Cancer - Pipeline by Batu Biologics Inc, H1 2018
  • Colon Cancer - Pipeline by Bayer AG, H1 2018
  • Colon Cancer - Pipeline by BCN Biosciences LLC, H1 2018
  • Colon Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Colon Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2018
  • Colon Cancer - Pipeline by BioCancell Ltd, H1 2018
  • Colon Cancer - Pipeline by Biogazelle NV, H1 2018
  • Colon Cancer - Pipeline by Blirt SA, H1 2018
  • Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Colon Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2018
  • Colon Cancer - Pipeline by Celgene Corp, H1 2018
  • Colon Cancer - Pipeline by Cellective BioTherapy Inc, H1 2018
  • Colon Cancer - Pipeline by Celprogen Inc, H1 2018
  • Colon Cancer - Pipeline by Chem-Master International Inc, H1 2018
  • Colon Cancer - Pipeline by CytomX Therapeutics Inc, H1 2018
  • Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2018
  • Colon Cancer - Pipeline by CZ BioMed Corp, H1 2018
  • Colon Cancer - Pipeline by Debiopharm International SA, H1 2018
  • Colon Cancer - Pipeline by DEKK-TEC Inc, H1 2018
  • Colon Cancer - Pipeline by Eli Lilly and Co, H1 2018
  • Colon Cancer - Pipeline by Enterome Bioscience SA, H1 2018
  • Colon Cancer - Pipeline by EntreChem SL, H1 2018
  • Colon Cancer - Pipeline by EnzymeBioSystems, H1 2018
  • Colon Cancer - Pipeline by Evotec AG, H1 2018
  • Colon Cancer - Pipeline by F-star Biotechnology Ltd, H1 2018
  • Colon Cancer - Pipeline by Felicitex Therapeutics Inc, H1 2018
  • Colon Cancer - Pipeline by Fujifilm Holdings Corporation, H1 2018
  • Colon Cancer - Pipeline by Fusion Pharmaceuticals Inc, H1 2018

List of Figures

  • Number of Products under Development for Colon Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2018, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 12, 40, 3, 169, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 43 and 15 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Colon Cancer - Overview
  • Colon Cancer - Therapeutics Development
  • Colon Cancer - Therapeutics Assessment
  • Colon Cancer - Companies Involved in Therapeutics Development
  • Colon Cancer - Drug Profiles
  • Colon Cancer - Dormant Projects
  • Colon Cancer - Discontinued Products
  • Colon Cancer - Product Development Milestones
  • Appendix
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research